Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Multiplicity

After years of growing momentum, 2015 saw the biosimilar genie fully emerge from the bottle

Eli Lilly HQ

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

EU flag

Sandoz files for approval of Neulasta biosimilar in Europe

Amgen facing increasing competition in global biosimilar market

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

dengue fever mosquito

Sanofi embarks on Zika vaccine hunt

Begins research programme as WHO declares the virus a global emergency

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links